Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
January 06, 2020 01:35 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, January 6, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by persons...
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer
January 06, 2020 01:35 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 6. januar 2020 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende...
Bavarian Nordic udsteder tegningsoptioner til nytiltrådt medlem af koncernledelsen
January 06, 2020 01:30 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 6. januar 2020 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabets bestyrelse har besluttet at udstede tegningsoptioner til Jean-Christophe May, der netop er tiltrådt...
Bavarian Nordic Issues Warrants to Newly Appointed Member of the Executive Management
January 06, 2020 01:30 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, January 6, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the Board of Directors in Bavarian Nordic A/S has decided to issue warrants to Jean-Christophe...
Bavarian Nordic Announces Closing of Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline and Updates Year-end Cash Preparedness
December 31, 2019 06:14 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, December 31, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that it has completed the acquisition of the manufacturing and global rights1 to the two commercial...
Bavarian Nordic afslutter købet af Rabipur/RabAvert og Encepur fra GlaxoSmithKline og justerer kapitalberedskabet ved årets udgang
December 31, 2019 06:14 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 31. december 2019 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har afsluttet købet af produktions- og globale rettigheder1 til de to kommercielle vacciner...
Bavarian Nordic Announces the Sale of Priority Review Voucher
December 17, 2019 13:36 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, December 17, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that it has entered an agreement to sell its Priority Review Voucher (PRV) for a total cash...
Bavarian Nordic offentliggør salget af Priority Review Voucher
December 17, 2019 13:36 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 17. december 2019 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået aftale om salg af sin Priority Review Voucher (PRV) for USD 95 mio. til en...
Bavarian Nordics køb af Rabipur/RabAvert og Encepur fra GlaxoSmithKline er godkendt af konkurrencemyndighederne
December 13, 2019 04:26 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 13. december 2019 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har fået godkendelse af konkurrencemyndighederne i USA, Spanien og Portugal af det planlagte køb af...
Bavarian Nordic Receives Antitrust Clearance for Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline
December 13, 2019 04:26 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, December 13, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that it has received antitrust clearance in the U.S., Spain and Portugal of its planned acquisition...